Morgan Stanley analyst Matthew Harrison raised his price target for Sarepta Therapeutics (SRPT) to $220 from $165 while keeping an Overweight rating on the shares. The stock closed Monday down $4.52 to $146.28. The company's Duchenne muscular dystrophy gene therapy is positioned to be the first to market, taking a majority share of the ~$20B prevalent population in the U.S. and expanding internationally with a "significant" lead, Harrison tells investors in a research note. He believes Sarepta has higher efficacy than top-line Pfizer (PFE) data suggest. Sarepta's dystrophin expression is likely three-times greater, fiber intensity 15%, and positive fibers 12.5%, contends the analyst. Harrison believes Sarepta has a "broad therapeutic window" and should now take majority market share.

Bullish option flow detected in Pfizer with 50,393 calls trading, 2x expected, and implied vol increasing over 2 points to 28.83%. Sep-24 27.5 calls and Mar-25 42.5 calls are the most active options, with total volume in those strikes near 27,600 contracts. The Put/Call Ratio is 0.21. Earnings are expected on May 1st.